Amgen Chairman and CEO Robert Bradway, provides insight to product innovation, the impact from the political cycle and the outlook for M&A. » Read More
These stocks to buy on a pullback are the least exposed to a potential European economic crisis, according to Morgan Stanley.
Biotech has been at a low year-to-date, but traders believe the sector is going to make a comeback.
The biotech sector has been sliding, but a turnaround could be afoot. Chad Morganlander of Stifel Nicolaus and Craig Johnson of Piper Jaffray discuss with Brian Sullivan.
Amgen is working on a drug to lower the risk of heart attack, reports CNBC's Meg Tirrell.
Nutanix is the biggest tech name on file for an IPO. While investors wait, its co-founder is bulking up a new company — ThoughtSpot.
A rare and previously unknown variation in some people's genes substantially reduces their heart attack risk, the Icelandic researchers said.
Pfizer will buy Anacor Pharmaceuticals in a deal valued at $5.2 billion, for access to Anacor's non-steroidal topical gel to treat eczema.
U.S. stocks closed mixed in below average trade volume Monday, with gains in health care offsetting declines in materials and energy as oil fell.
Biotech stocks dragged on the market Friday, and some "Fast Money" traders contended the pain may not be done.
Three pillars of valuation driving biotech with CNBC's Meg Tirrell while the Fast Money panel discuss biotech as their top trade of the day.
The "Fast Money" traders get into biotech and give you 5 trades in a mixed sector.
Some of the names on the move ahead of the open.
CNBC's Meg Tirrell reports on Amgen's quarterly results as the company raises guidance.
Options trader Dan Nathan says the biotech sector could get a boost on earnings.
U.S. stock index futures pointed to a mostly lower open Thursday as traders reacted to the Bank of Japan's (BOJ) decision to keep monetary policy steady.
Potential market cap swings in biotech with CNBC contributor Dan Nathan.
Discussing the best investment strategy right now, demand for stocks, and whether individual investors should be worried about hedge funds' picks, with Heidi Richardson, BlackRock, and Nancy Tengler, Heartland Financial.
Seattle is no Silicon Valley, but the home city of Amazon and Microsoft is a hotbed for innovation in its own right.
As the first quarter comes to a close, one sector notably stands out in the negative column: biotech.
CNBC's Meg Tirrell reports on Alder Biopharmaceuticals' chronic migraine drug trial and how other pharma companies are developing new treatments and therapies, as well as the latest on Valeant CEO Mike Pearson's subpoena.